ALK and lung adenocarcinoma: Despite the potential benefits of inhibition of ALK in patients with SDC with rearranged HNRNPH3-ALK tumors, established knowledge of lung adenocarcinoma, a cancer with a similar genetic makeup, may guide treatment decisions in SDC with genetically similar tumors [38].